Literature DB >> 3467121

Pancreatic carcinogenesis: effect of secretin in the hamster- nitrosamine model.

A G Howatson, D C Carter.   

Abstract

The effect of exogenous secretin on pancreatic carcinogenesis in WO strain hamsters has been examined in the nitrosamine-ductular adenocarcinoma model. Secretin, 20 clinical U/kg, stimulated a maximal secretory response of pancreatic juice and bicarbonate when given iv. The same dose given sc for 6 weeks had no significant effect on pancreatic wet weight and DNA or RNA contents. However, when given to animals receiving N-nitrosobis(2-oxopropyl)amine [(BOP) CAS: 60599-38-4] (5 mg/kg), it reduced the latency and increased the induction rate of tumor development when compared with the carcinogen given alone to animals (secretin + BOP, 15 of 17 animals with tumors; BOP alone, 4 of 13 with tumors at 15 wk; P less than .002). These effects are consistent with secretin acting as a cocarcinogen in this model of pancreatic carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3467121     DOI: 10.1093/jnci/78.1.101

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  Pancreatic cancer and exposure to dietary nitrate and nitrite in the NIH-AARP Diet and Health Study.

Authors:  Briseis Aschebrook-Kilfoy; Amanda J Cross; Rachael Z Stolzenberg-Solomon; Arthur Schatzkin; Albert R Hollenbeck; Rashmi Sinha; Mary H Ward
Journal:  Am J Epidemiol       Date:  2011-06-17       Impact factor: 4.897

2.  Helicobacter pylori infection, atrophic gastritis, and risk of pancreatic cancer: A population-based cohort study in a large Japanese population: the JPHC Study.

Authors:  Mayo Hirabayashi; Manami Inoue; Norie Sawada; Eiko Saito; Sarah K Abe; Akihisa Hidaka; Motoki Iwasaki; Taiki Yamaji; Taichi Shimazu; Shoichiro Tsugane
Journal:  Sci Rep       Date:  2019-04-15       Impact factor: 4.379

3.  Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.

Authors:  B Szende; A Zalatnai; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

4.  Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. Histological evidence of improvement.

Authors:  A Zalatnai; A V Schally
Journal:  Int J Pancreatol       Date:  1989-03

Review 5.  Pancreatic cancer - a continuing challenge in oncology.

Authors:  Attila Zalatnai
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

Review 6.  Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma.

Authors:  W E Fisher; P Muscarella; L G Boros; W J Schirmer
Journal:  Int J Pancreatol       Date:  1998-12

Review 7.  Biology of pancreatic cancer.

Authors:  G J Poston; J Gillespie; P J Guillou
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

8.  History of peptic ulcer disease and pancreatic cancer risk in men.

Authors:  Ying Bao; Donna Spiegelman; Ruifeng Li; Edward Giovannucci; Charles S Fuchs; Dominique S Michaud
Journal:  Gastroenterology       Date:  2009-10-07       Impact factor: 22.682

Review 9.  Helicobacter pylori infection: new pathogenetic and clinical aspects.

Authors:  Krisztina Hagymási; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

10.  Synthesis and characterization of oligodeoxyribonucleotides containing a site-specifically incorporated N6-carboxymethyl-2'-deoxyadenosine or N4-carboxymethyl-2'-deoxycytidine.

Authors:  Jianshuang Wang; Yinsheng Wang
Journal:  Nucleic Acids Res       Date:  2010-05-27       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.